CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Hold” from Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned an average recommendation of “Hold” from the nineteen brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $74.94.

Several research firms have recently weighed in on CRSP. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Chardan Capital lowered their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $55.15 on Tuesday. The firm has a market capitalization of $4.71 billion, a P/E ratio of -19.49 and a beta of 1.67. The company’s fifty day moving average price is $48.30 and its 200-day moving average price is $51.58. CRISPR Therapeutics has a 1-year low of $43.42 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same period in the previous year, the company posted ($1.41) earnings per share. Equities analysts anticipate that CRISPR Therapeutics will post -5.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,382 shares of company stock valued at $1,917,679 over the last three months. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently made changes to their positions in CRSP. Cetera Investment Advisers increased its stake in shares of CRISPR Therapeutics by 451.3% during the 1st quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock worth $2,324,000 after purchasing an additional 27,915 shares during the last quarter. CWM LLC increased its position in CRISPR Therapeutics by 11,871.1% during the second quarter. CWM LLC now owns 22,386 shares of the company’s stock worth $1,209,000 after buying an additional 22,199 shares during the last quarter. Capital Advisors Inc. OK raised its holdings in CRISPR Therapeutics by 8.1% during the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after buying an additional 22,583 shares in the last quarter. Granite Bay Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the second quarter worth about $2,375,000. Finally, International Assets Investment Management LLC bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $1,825,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.